Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active anti-tumor immunity | Immunology and Biotherapies | Scoop.it
From www.landesbioscience.com - October 29, 2014 2:50 PM

AbstractWe have recently reported that LAG-3 (CD223) mediates the alternative, IFNα-deficient activation of pDCs at tumor sites. Our findings define a novel tumor-driven strategy that promotes immunosuppression by pDCs, and we have provided more detailed information regarding the immunomodulatory role of LAG-3. The translational relevance of our results for the treatment of tumors and autoimmune diseases is discussed herein.


Via Krishan Maggon